FDA’s McClellan To Head CMS: Will Greater FDA/CMS Cooperation Ensue?
Executive Summary
FDA Commissioner McClellan's nomination to be administrator of the Centers for Medicare & Medicaid Services could usher in an era of increased cooperation between the two agencies
You may also be interested in...
Drug-Eluting Stents Will Be Model For CMS/FDA Cooperation – McClellan
The drug-eluting stent approval and reimbursement process should serve as a model for how CMS and FDA can work more closely together to ensure coverage for new technologies, CMS Administrator Mark McClellan told the Food & Drug Law Institute conference in Washington, D.C. April 15
Drug-Eluting Stents Will Be Model For CMS/FDA Cooperation – McClellan
The drug-eluting stent approval and reimbursement process should serve as a model for how CMS and FDA can work more closely together to ensure coverage for new technologies, CMS Administrator Mark McClellan told the Food & Drug Law Institute conference in Washington, D.C. April 15
McClellan Changing Agencies, Not Mission; CMS, FDA Both Promote “Access”
Medical innovation should be the focus of the Centers for Medicare & Medicaid Services just as it is at FDA, Commissioner McClellan said